Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01592084 · ClinicalTrials.gov registry record
Hyperlipidemia and Statin Therapy in Amyotrophic Lateral Sclerosis
A clinical trial, sponsored by The Methodist Hospital Research Institute.
- Completed
- Registry status
- 267
- Enrollment target
NCT01592084: Completed study, sponsored by The Methodist Hospital Research Institute.
NCT01592084 is a clinical trial that has completed, run by The Methodist Hospital Research Institute. The registered enrollment target is 267 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01592084 has completed, sponsored by The Methodist Hospital Research Institute.
- COMPLETED
- Registry status
- 267 participants
- Enrollment target
Study Summary
The role of hyperlipidemia and lipid lowering therapy (LLT) in Amyotrophic Lateral Sclerosis (ALS) pathophysiology and its impact on disease progression and survival is unclear. The investigators analyzed the correlation between lipid levels with disease progression and survival in ALS patients and the association of LLT with these outcomes.
Primary Outcome
Death was confirmed from Social Security Death Index or newspaper obituaries. Tracheostomy- ventilation was also considered as an end of the life time point.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 267 participants |
| Start Date | 2008-04 |
| Est. Completion | 2011-09 |
What the finished NCT01592084 record still lists
NCT01592084 is an observational study that tracks outcomes without assigning an intervention. The registered 267 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01592084 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01592084 about?
NCT01592084 is a clinical study titled "Hyperlipidemia and Statin Therapy in Amyotrophic Lateral Sclerosis". The role of hyperlipidemia and lipid lowering therapy (LLT) in Amyotrophic Lateral Sclerosis (ALS) pathophysiology and its impact on disease progression and survival is unclear. The investigators analyzed the correlation between lipid levels with disease progression and survival in ALS patients and ...
What is the current status of trial NCT01592084?
This trial is currently completed. The enrollment target is 267 participants. The study started on 2008-04. Estimated completion is 2011-09.
Who is sponsoring clinical trial NCT01592084?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04997109 · 267 participants · NA
Telemedicine in Early Childhood Constraint Therapy in Cerebral Palsy
- NCT05355701 · 267 participants · Phase 1
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
- NCT06203509 · 267 participants · NA
Improving Care Transitions for Medicaid Insured Individuals With Co-occurring Serious Mental Illness
- NCT05000632 · 268 participants · NA
Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia